| Literature DB >> 24675384 |
A Ling1, S Edin1, M L Wikberg1, Å Öberg2, R Palmqvist1.
Abstract
BACKGROUND: To find improved tools for prognostic evaluation in patients with colorectal cancer (CRC), we have analysed how infiltration of cytotoxic T lymphocytes (CD8(+)) and regulatory T lymphocytes (FoxP3(+)) correlates to prognosis, not only according to quantity and relation, but also to subsite within tumours of different molecular characteristics (microsatellite instability and CpG island methylator phenotype status).Entities:
Mesh:
Substances:
Year: 2014 PMID: 24675384 PMCID: PMC4021513 DOI: 10.1038/bjc.2014.161
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Evaluation of immune marker expression at intratumoural subsites of colon carcinoma. Expression of CD8+ cells determined by immunohistochemistry at the invasive front, tumour centre and within the tumour epithelium (intraepithelial expression, indicated by arrows).
Cross-tabulation between total score for CD8 and FOXP3 expression in CRC
| | | |||
|---|---|---|---|---|
| 3–4 | 17 (34.7) | 28 (57.1) | 4 (8.2) | <0.001 |
| 5–6 | 25 (20.7) | 69 (57.0) | 27 (22.3) | |
| 7–12 | 27 (12.6) | 98 (45.6) | 90 (41.9) | |
Exact linear-by-linear association test.
Total score for CD8 and FOXP3 expression in relation to clinicopathologic characteristics in CRC
| | | | ||||||
|---|---|---|---|---|---|---|---|---|
| Frequency (%) | 55 (13.7) | 128 (31.8) | 219 (54.5) | | 79 (19.5) | 201 (49.6) | 125 (30.9) | |
| Gender, | | | | 0.781 | | | | 0.178 |
| Male | 28 (12.6) | 71 (32.0) | 123 (55.4) | 42 (18.7) | 105 (46.7) | 78 (34.7) | ||
| Female | 27 (15.0) | 57 (31.7) | 96 (53.3) | | 37 (20.6) | 96 (53.3) | 47 (26.1) | |
| Age, | | | | 0.001/0.086 | | | | 0.147/0.446 |
| ⩽59 | 6 (8.3) | 22 (30.6) | 44 (61.1) | 16 (22.2) | 30 (41.7) | 26 (36.1) | ||
| 60–69 | 23 (21.9) | 38 (36.2) | 44 (41.9) | 26 (25.2) | 45 (43.7) | 32 (31.1) | ||
| 70–79 | 19 (14.0) | 50 (36.8) | 67 (49.3) | 27 (19.1) | 76 (53.9) | 38 (27.0) | ||
| ⩾80 | 7 (7.9) | 18 (20.2) | 64 (71.9) | | 10 (11.2) | 50 (56.2) | 29 (32.6) | |
| Localisation, | | | | 0.001/0.003 | | | | 0.356/0.857 |
| Right colon | 15 (11.6) | 28 (29.5) | 76 (58.9) | 26 (20.0) | 59 (45.4) | 45 (34.6) | ||
| Left colon | 7 (5.7) | 38 (31.1) | 77 (63.1) | 27 (21.6) | 68 (54.4) | 30 (24.0) | ||
| Rectum | 32 (21.6) | 50 (33.8) | 66 (44.6) | | 26 (17.7) | 72 (49.0) | 49 (33.3) | |
| Stage, | | | | 0.030/0.047 | | | | <0.001/<0.001 |
| I | 8 (12.7) | 20 (31.7) | 35 (55.6) | 4 (6.3) | 23 (36.5) | 36 (57.1) | ||
| II | 16 (10.5) | 42 (27.6) | 94 (61.8) | 25 (15.9) | 78 (49.7) | 54 (34.4) | ||
| III | 17 (20.0) | 23 (27.1) | 45 (52.9) | 15 (18.1) | 50 (60.2) | 18 (21.7) | ||
| IV | 12 (12.8) | 42 (44.7) | 40 (42.6) | | 35 (37.2) | 44 (46.8) | 15 (16.0) | |
| Grade, | | | | 0.077 | | | | 0.321/0.193 |
| Low | 21 (10.3) | 63 (31.0) | 119 (58.6) | 38 (18.7) | 96 (47.3) | 69 (34.0) | ||
| High | 33 (17.1) | 65 (33.7) | 95 (49.2) | | 41 (20.9) | 102 (52.0) | 53 (27.0) | |
| Growth pattern, | | | | 0.003 | | | | 0.866 |
| Pushing | 16 (12.3) | 28 (21.5) | 86 (66.2) | 26 (19.7) | 63 (47.7) | 43 (32.6) | ||
| Infiltrating | 37 (14.0) | 98 (37.0) | 130 (49.1) | | 52 (19.4) | 135 (50.4) | 81 (30.2) | |
| Histology type, | | | | 0.231 | | | | 0.260 |
| Mucinous | 5 (9.3) | 22 (40.7) | 27 (50.0) | 15 (27.3) | 25 (45.5) | 15 (27.3) | ||
| Non-mucinous | 50 (14.5) | 103 (29.9) | 191 (55.5) | | 62 (17.9) | 174 (50.3) | 110 (31.8) | |
| Preoperative radiation therapy | | | | <0.001 | | | | 0.923 |
| No | 5 (7.7) | 18 (27.7) | 42 (64.6) | 11 (17.5) | 32 (50.8) | 20 (31.7) | ||
| Yes | 27 (32.5) | 32 (38.6) | 24 (28.9) | 15 (17.9) | 40 (47.9) | 29 (34.5) | ||
Unless otherwise indicated, χ2 test was used for categorical variables.
Exact linear-by-linear association test was used to test for linear relationship between variables.
Preoperative radiation therapy in rectal cancers only.
Figure 2Cancer-specific survival in colon cancers. Cases scored (A) for expression of CD8 and FOXP3 total score: score 3–4 (low), 5–6 (moderate) or 7–12 (abundant) expression; or (B) at intratumoural subsites, CD8 IE (intraepithelial) and FOXP3 F (front), score 1–4: score 1 (no/sporadic), score 2 (moderate), score 3 (abundant) and score 4 (highly abundant). Shown are Kaplan–Meier plots. Log-rank tests were used to calculate P values.
Figure 3Cancer-specific survival of colon cancers. Cases scored for the quotient of (A) the total score: score 3–4 (low), 5–6 (moderate) or 7–12 (abundant) of CD8/FOXP3 expression; or (B) CD8 IE/FOXP3 F, score 1–4: score 1 (no/sporadic), score 2 (moderate), score 3 (abundant) and score 4 (highly abundant). (C) Cancer-specific survival of cases scored for subgroups of CD8Lo, score 1–2; CD8Hi, score 3–4; FOXP3Lo, score 1–2; and FOXP3Hi, score 3–4. Shown are Kaplan–Meier plots. Log-rank tests were used to calculate P values.
CD8 and FOXP3 total score and expression at intratumoural subsites in relation to molecular characteristics in colon cancers
| | | | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MSI screening status | | | | | 0.128 | | | | | 0.035 |
| MSI | 3 (6.1) | 10 (20.4) | 36 (73.5) | 14 (26.9) | 18 (34.6) | 20 (38.5) | ||||
| MSS | 19 (9.7) | 64 (32.7) | 113 (57.7) | | | 37 (18.8) | 108 (54.8) | 52 (26.4) | | |
| CIMP status | | | | | 0.983 | | | | | 0.927 |
| CIMP-negative | 10 (9.7) | 30 (29.1) | 63 (61.2) | 19 (18.4) | 54 (52.4) | 30 (29.1) | ||||
| CIMP-low | 9 (8.7) | 32 (30.8) | 63 (60.6) | 24 (22.9) | 51 (48.6) | 30 (28.6) | ||||
| CIMP-high | 3 (6.8) | 14 (31.8) | 27 (61.4) | | | 10 (21.3) | 22 (46.8) | 15 (31.9) | | |
| | | |||||||||
| MSI screening status | | | | | 0.004 | | | | | 0.201 |
| MSI | 1 (2.0) | 5 (10.2) | 21 (42.9) | 22 (44.9) | 9 (17.3) | 21 (40.4) | 16 (30.8) | 6 (11.5) | ||
| MSS | 13 (6.6) | 57 (29.1) | 79 (40.3) | 47 (24.0) | | 29 (14.7) | 102 (51.8) | 57 (28.9) | 9 (4.6) | |
| CIMP status | | | | | 0.244 | | | | | 0.849 |
| CIMP-negative | 9 (8.7) | 26 (25.2) | 39 (37.9) | 29 (28.2) | 13 (12.6) | 55 (53.4) | 29 (28.2) | 6 (5.8) | ||
| CIMP-low | 4 (3.8) | 27 (26.0) | 48 (46.2) | 25 (24.0) | 19 (18.1) | 48 (45.7) | 33 (31.4) | 5 (4.8) | ||
| CIMP-high | 1 (2.3) | 10 (22.7) | 15 (34.1) | 18 (40.9) | | 7 (14.9) | 22 (46.8) | 14 (29.8) | 4 (8.5) | |
| | | | | | | | | | | |
| MSI screening status | | | | | 0.023 | | | | | 0.175 |
| MSI | 3 (6.0) | 14 (28.0) | 21 (42.0) | 12 (24.0) | 13 (24.5) | 19 (35.8) | 17 (32.1) | 4 (7.5) | ||
| MSS | 16 (8.0) | 82 (40.8) | 85 (42.3) | 18 (9.0) | | 27 (13.4) | 98 (48.8) | 64 (31.8) | 12 (6.0) | |
| CIMP status | | | | | 0.336 | | | | | 0.422 |
| CIMP-negative | 6 (5.6) | 42 (39.3) | 50 (46.7) | 9 (8.4) | 13 (12.4) | 53 (50.5) | 29 (27.6) | 10 (9.5) | ||
| CIMP-low | 10 (9.5) | 38 (36.2) | 44 (41.9) | 13 (12.4) | 20 (18.5) | 45 (41.7) | 38 (35.2) | 5 (4.6) | ||
| CIMP-high | 3 (6.7) | 19 (42.2) | 14 (31.1) | 9 (20.0) | | 9 (19.1) | 20 (42.6) | 16 (34.0) | 2 (4.3) | |
| | | | | | | | | | | |
| MSI screening status | | | | | <0.001 | | | | | |
| MSI | 14 (28.0) | 11 (22.0) | 14 (28.0) | 11 (22.0) | ||||||
| MSS | 93 (46.3) | 59 (29.4) | 39 (19.4) | 10 (5.0) | | | | | | |
| CIMP status | | | | | 0.553 | | | | | |
| CIMP-negative | 44 (41.1) | 32 (29.9) | 24 (22.4) | 7 (6.5) | ||||||
| CIMP-low | 48 (45.7) | 29 (27.6) | 20 (19.0) | 8 (7.6) | ||||||
| CIMP-high | 17 (37.8) | 10 (22.2) | 11 (24.4) | 7 (15.6) | ||||||
Abbreviations: CIMP= CpG island methylator phenotype; MSI= microsatellite unstable; MSS= microsatellite stable.
Unless otherwise indicated, χ2 test was used for categorical variables.
Cases lacking nuclear staining of tumour cells for at least one of MLH1, MSH2, MSH6 or PMS2 were considered to have a positive MSI screening status.
Phenotype determined according to hypermethylation of an eight-gene panel with the following number of hypermethylated genes found for CIMP-negative, 0 genes; CIMP-low, 1–5 genes; and CIMP-high, 6–8 genes.
Figure 4Cancer-specific survival in subgroups of colon cancer arranged according to MSI screening status. Cases scored for CD8 IE or FOXP3 F expression, score 1–4: score 1 (no/sporadic), score 2 (moderate), score 3 (abundant) and score 4 (highly abundant). Shown are Kaplan–Meier plots of specimens of (A) MSI cases and (B) MSS cases. Log-rank tests were used to calculate P values.